# What Happens When You Stop Taking Wegovy Tablets?
This is one of the most important questions anyone starting oral Wegovy should ask — and one that does not get answered clearly enough by the promotional content surrounding GLP-1 medications. The honest answer is difficult for some people to hear: for the majority of patients who stop taking Wegovy tablets, most of the weight they lost returns within one to two years. This is not a sign that the drug failed. It is how the drug works — and understanding this from the start changes how you should think about this treatment.
> Wegovy tablets are a prescription-only medicine. Always consult a qualified healthcare professional before starting or changing treatment. Never stop or pause your medication without first discussing it with your prescriber.
—
## The honest answer
Semaglutide works while you take it. The drug’s appetite-suppressive effects, its slowing of gastric emptying, and its action on brain circuits that govern hunger and food reward are all active only while semaglutide is present in the body. When the drug is stopped, blood semaglutide levels fall over one to two weeks (the half-life of semaglutide is approximately one week). As levels fall, the biological effects diminish and appetite returns — often strongly.
Most people find that within a month of stopping, their appetite has largely returned to where it was before treatment. The “food noise” — the constant mental preoccupation with eating, cravings, and hedonic food interest — comes back. Without the pharmacological suppression of appetite, maintaining the calorie deficit that produced weight loss becomes considerably harder. Body weight typically trends back toward the pre-treatment set point.
This is not a moral failing. Obesity is a chronic condition with strong biological drivers. Treating it with a drug that addresses those biological drivers works — while you use the drug. Stopping the drug removes the treatment, and the condition reasserts itself. The parallel to blood pressure medication is directly applicable: stopping antihypertensives causes blood pressure to rise again. No one interprets this as evidence that the medication “didn’t work.”
—
## What the evidence says about weight regain
The most relevant evidence comes from the STEP 4 trial, which was conducted with injectable Wegovy (2.4mg weekly semaglutide) but used the same active ingredient as oral Wegovy. In STEP 4, participants who had lost weight during the initial treatment phase were randomly assigned to either continue semaglutide or switch to placebo. Those who switched to placebo regained approximately 7.9% of body weight within the first year. The group that continued treatment maintained their weight loss and lost a further small amount.
At the two-year point after stopping, the majority of weight regained in the placebo group had returned. Participants who had achieved significant weight loss during treatment approached their pre-treatment weight over time after stopping. The speed of regain varies between individuals — some regain faster, some more slowly — but the direction of the trend is consistent across most of the evidence base.
For oral Wegovy specifically, the OASIS 4 trial did not include a withdrawal phase with long-term follow-up, so direct oral-tablet specific data on regain timelines is not yet published. The pharmacological mechanism is identical to the injection, so the regain pattern is expected to be similar.
—
## Why the weight returns
When you take semaglutide, several things happen simultaneously. The drug reduces levels of ghrelin, the hormone most responsible for hunger signalling. It slows gastric emptying, so food stays in the stomach longer and you feel full sooner and for longer. It acts on hypothalamic appetite centres in the brain, reducing the neurological reward response to calorie-dense food. It also improves insulin secretion and glucose handling, which affects fat storage dynamics.
When the drug is stopped, all of these effects reverse. Ghrelin levels rise back toward baseline. Gastric emptying returns to its normal rate. The neurological reward associated with food returns to pre-treatment levels. The body, which has been defending a biological set point that the drug was suppressing, begins to actively restore that set point. Appetite increases, often more than patients expect, and the effort required to resist eating more increases substantially.
There is also a secondary physiological factor: weight loss itself reduces metabolic rate. A person who has lost 15kg has a lower resting metabolic rate than they had at their pre-treatment weight, because metabolic rate scales with body mass. This means that at their lower weight, they need fewer calories to maintain that weight — but their appetite (absent the drug) is calibrated to a higher intake. This combination of higher appetite and lower metabolic need creates a powerful biological pressure to regain weight.
—
## What you can keep after stopping
Not everything is lost when you stop treatment. Habits genuinely established during treatment — particularly structural changes to eating patterns, portion awareness, and reduced intake of highly processed foods — can persist to some degree. Patients who used the treatment period to actively rebuild their relationship with food and to establish new routines tend to fare better after stopping than those who relied entirely on the drug’s pharmacological effect without any behavioural change alongside it.
Physical fitness gained during treatment is also retained independently of the medication. Muscle mass built through resistance training during the treatment period has its own metabolic benefit and does not disappear when the drug stops. Similarly, improvements in blood pressure, blood glucose, and cardiovascular markers that accompanied weight loss often persist for some months after stopping, gradually returning to pre-treatment levels as weight is regained.
The honest picture is that stopping oral Wegovy is not a total reset — but it is, for most people, a significant step backward if the intention was to maintain the weight lost.
—
## When stopping is medically necessary
There are clinical circumstances in which stopping oral Wegovy is required or strongly indicated. Pregnancy planning is one of the most common: semaglutide is not recommended for use during pregnancy, and current guidance is to stop treatment at least two months before attempting to conceive. Some anaesthetists and surgical teams request a hold on GLP-1 treatment before elective procedures due to concerns about residual gastric slowing affecting anaesthetic risk; patients should discuss surgical planning with both their prescriber and surgical team.
Serious adverse events, including pancreatitis or significant gallbladder disease, require immediate cessation and clinical review. Some patients stop due to tolerability — persistent severe GI side effects that do not resolve. And some stop for financial reasons, particularly given the current private-only status of oral Wegovy in the UK.
—
## Coming off gradually versus stopping suddenly
There is no established clinical tapering protocol for oral semaglutide. The drug’s half-life means that blood levels fall gradually over one to two weeks after stopping, so there is a built-in partial taper simply from discontinuation. Some prescribers may reduce the dose before stopping rather than halting abruptly, particularly for patients who have been on higher doses for extended periods. Your prescriber should guide this decision. Do not reduce or stop your dose without clinical advice.
—
## The long-term picture
The emerging clinical consensus, in the UK and internationally, is that GLP-1 treatment for obesity is most effective when approached as a long-term or lifelong management strategy, in the same way that antihypertensives or statins are used for chronic conditions. The expectation that a two-year course of a weight loss drug should produce permanent results without ongoing treatment reflects a misunderstanding of obesity as a condition rather than a lifestyle choice.
Whether oral Wegovy becomes a long-term option for any individual depends on affordability, NHS access, and their prescriber’s clinical judgement. The goal of securing NHS commissioning of oral semaglutide — currently not started — is to make long-term access realistic for patients who need sustained treatment.
—
## Frequently asked questions
### Will I definitely gain all my weight back if I stop Wegovy tablets?
The majority of clinical evidence shows significant weight regain after stopping semaglutide, but the rate and extent varies between individuals. Factors that influence how much weight returns include: how long you were on treatment, what lifestyle changes you established during treatment, your individual metabolic baseline, and whether you remain active. For most people, a meaningful proportion of lost weight returns, though the speed varies.
### Can I pause and then restart oral Wegovy?
Technically yes — there is no medical reason why you cannot stop and restart semaglutide. However, restarting typically requires returning to the starting dose and re-escalating, which means going through the initial side effect phase again. Frequent stopping and starting is not ideal from a pharmacological standpoint. If cost is the driver, speak to your prescriber about whether staying at a lower maintenance dose is a better option than stopping completely.
### How quickly does appetite return after stopping?
For most people, appetite begins returning noticeably within one to two weeks of stopping, tracking the decline in blood semaglutide levels. The “food noise” — preoccupation with eating and food cravings — typically returns over a similar timeframe. By four weeks after stopping, most patients report that appetite has largely returned to pre-treatment levels.
### Is there a maintenance dose you can take to prevent regain?
In clinical terms, the maintenance dose is 25mg — the dose used in the long-term trials. There is no established sub-maintenance dose protocol for weight maintenance in the same way that there is for some other medications. Continuing at the therapeutic dose is the evidence-based approach for maintaining weight loss. Some prescribers may trial lower doses for maintenance if full-dose side effects are a concern; this is a clinical discussion between you and your prescriber.
### Does the drug “stop working” or does weight return because you stop the drug?
It returns because you stop the drug. This distinction matters. If weight returns after stopping semaglutide, it is evidence that you needed the drug to maintain the reduced weight — not evidence that the drug stopped working. In clinical trials, weight loss at maximum dose is maintained for as long as the drug is continued. Regain after stopping is not drug failure; it is cessation of an active treatment for a chronic condition.
—
*This article is for informational purposes only and does not constitute medical advice. Wegovy tablets (oral semaglutide) are a prescription-only medicine available in the UK. Always consult a registered UK healthcare professional before starting or stopping any weight management treatment. CompareWegovyPrices.co.uk is not affiliated with Novo Nordisk.*